The Pharmaceutical Journal
Vol 277 No 7431 p729
16 December 2006

This article
Reprint   Photocopy

  Acrobat Reader

News summary

Pfizer pulls plug on its HDL improving drug torcetrapib

Pfizer has ceased development of its investigational cardiovascular therapy torcetrapib because of safety concerns.

The drug, designed to increase high-density lipoprotein levels, was being tested in a large Phase III trial. However, the trial’s independent data safety monitoring board recommended that the trial be suspended after data suggested that the drug, given in combination with atorvastatin, was associated with increased mortality compared with atorvastatin alone.